
    
      Enroll patients after confirming eligibility. Following enrollment, peripheral blood
      mononuclear cells and blood plasma will be obtained from each subject by apheresis to start
      the manufacturing of TBI-1501.

      Before TBI-1501 administration, it is necessary to pass the quality tests. Subject will be
      hospitalized from Day -3 to Day 28, and administered Cyclophosphamide (1,000 mg/m2/day√ó2
      days) on Day -3 and Day -2.
    
  